Coherus BioSciences (CHRS) Reports Q2 Loss of $1.56
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.20 +5.26%
Financial Fact:
Cost of goods sold: 219.53M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Cost of goods sold: 219.53M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($1.56), versus ($5.90) reported last year. Revenue for the quarter came in at $6.87 million, versus $4.46 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
